HEPATIC IMPAIRMENT MEASURED BY QUANTITATIVE TESTS OF LIVER FUNCTION (QLFTS) PREDICTS CLINICAL OUTCOME IN PATIENTS WITH ADVANCED FIBROSIS: RESULTS FROM THE HEPATITIS C ANTIVIRAL LONG-TERM TREATMENT AGAINST CIRRHOSIS (HALT-C) TRIAL

被引：0
|
作者：
Everson, Gregory T. [1 ]
Hoefs, John C. [2 ]
Shiffman, Mitchell L. [3 ]
Morgan, Timothy R. [2 ]
Sterling, Richard K. [3 ]
Curto, Teresa M. [5 ]
Wagner, David [4 ]
Wright, Elizabeth C. [6 ]
Everhart, James E. [6 ]
机构：
[1] Univ Colorado, Transplant Ctr & Hepatol, Aurora, CO USA
[2] Univ Calif Irvine, Div Gastroenterol & Hepatol, Irvine, CA USA
[3] VCU, Sect Hepatol, Richmond, VA USA
[4] Metab Solut, Nashua, NH USA
[5] New England Res Inst, Watertown, MA 02172 USA
[6] NIDDK, Bethesda, MD USA
来源：
HEPATOLOGY | 2009年 / 50卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1627
引用
收藏
页码：1057A / 1058A
页数：2
相关论文
共 50 条
  • [21] Portal hypertensive gastropathy in chronic hepatitis C patients with bridging fibrosis and compensated cirrhosis: Results from the HALT-C trial
    Fontana, Robert J.
    Sanyal, Arun J.
    Mehta, Savant
    Doherty, Michael C.
    Neuschwander-Tetri, Brent A.
    Everson, Gregory T.
    Kahn, Jeffrey A.
    Malet, Peter F.
    Sheikh, Muhammad Y.
    Chung, Raymond T.
    Ghany, Marc G.
    Gretch, David R.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (05): : 983 - 992
  • [22] Altered hepatic metabolic function in patients with chronic hepatitis C is associated with obesity, insulin resistance, or hepatic steatosis, independent of cirrhosis: Results from the HALT-C Trial
    Everson, Gregory T.
    Kulig, Clark C.
    Shiffman, Mitchell L.
    Sterling, Richard K.
    Morgan, Timothy R.
    Hoefs, John C.
    Curto, Teresa M.
    Everhart, James E.
    Wagner, David
    HEPATOLOGY, 2006, 44 (04) : 299A - 299A
  • [23] The spectrum of hepatic functional impairment in compensated chronic hepatitis C: results from the hepatitis C anti-viral long-term treatment against cirrhosis trial
    Everson, G. T.
    Shiffman, M. L.
    Morgan, T. R.
    Hoefs, J. C.
    Sterling, R. K.
    Wagner, D. A.
    Kulig, C. C.
    Curto, T. M.
    Wright, E. C.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2008, 27 (09) : 798 - 809
  • [24] Prognostic Value of Ishak Fibrosis Stage: Findings from the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial
    Everhart, James E.
    Wright, Elizabeth C.
    Goodman, Zachary D.
    Dienstag, Jules L.
    Hoefs, John C.
    Kleiner, David E.
    Ghany, Marc G.
    Mills, A. Scott
    Nash, S. Russell
    Govindarajan, Sugantha
    Rogers, Thomas E.
    Greenson, Joel K.
    Brunt, Elizabeth M.
    Bonkovsky, Herbert L.
    Morishima, Chihiro
    Litman, Heather J.
    HEPATOLOGY, 2010, 51 (02) : 585 - 594
  • [25] Silymarin use and liver disease progression in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis trial
    Freedman, N. D.
    Curto, T. M.
    Morishima, C.
    Seeff, L. B.
    Goodman, Z. D.
    Wright, E. C.
    Sinha, R.
    Everhart, J. E.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 33 (01) : 127 - 137
  • [26] RATE OF PROGRESSION OF HEPATIC FIBROSIS IN PATIENT WITH CHRONIC HEPATITIS C (CHC) PREDICTS NON-HCC AND HCC OUTCOMES: RESULTS FROM THE HALT-C TRIAL
    Hoofs, John C.
    Shiffman, Mitchell L.
    Goodman, Zachary
    Kleiner, David E.
    Stoddard, Anne M.
    Dienstag, Jules L.
    HEPATOLOGY, 2010, 52 (04) : 412A - 412A
  • [27] NON-INVASIVE MEASUREMENT OF HEPATIC FIBROSIS FROM THE QUANTITATIVE LIVER-SPLEEN SCAN (QLSS): HALT-C TRIAL RESULTS
    Hoefs, John C.
    Everson, Gregory T.
    Shiffman, Mitchell L.
    Morgan, Timothy
    Chen, Wen-Pin
    Gillen, Daniel
    HEPATOLOGY, 2011, 54 : 569A - 570A
  • [28] Dietary Cholesterol Intake Is Associated With Progression of Liver Disease in Patients With Chronic Hepatitis C: Analysis of the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial
    Yu, Lei
    Morishima, Chihiro
    Ioannou, George N.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2013, 11 (12) : 1661 - U208
  • [29] Automated summaries of serious adverse events in the hepatitis C antiviral long-term treatment against cirrhosis trial
    Bell, Margaret C.
    Robuck, Patricia R.
    Wright, Elizabeth C.
    Mihova, Marina S.
    Hofmann, Charlotte
    De Santo, Jennifer L.
    Milstein, Susan L.
    Richtmyer, Pamela A.
    Shelton, Janel L.
    Cormier, Maureen
    King, Debra L.
    Park, Choon J.
    Molchen, Wallis A.
    Park, Yoon
    Kelley, Michelle
    CLINICAL TRIALS, 2009, 6 (06) : 618 - 627
  • [30] Quantitative tests (QLFTS) detect impaired hepatic function in a high proportion of chronic hepatitis C patients with fibrosis or compensated cirrhosis and may predict risk of cirrhosis, splenomegaly, and varices.
    Everson, GT
    Kugelmas, M
    DeSanto, J
    Lauriski, S
    Shiffman, ML
    Sterling, R
    Charlotte, H
    Morgan, T
    Hoefs, J
    Milne, N
    Rietkerk, W
    Wagner, D
    Wright, E
    HEPATOLOGY, 2003, 38 (04) : 304A - 305A
12345